MedTrace Logo

A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers

NCT02197000 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2020-11-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether adding DIM supplement will decrease breast density among female BRCA mutation carriers in two years.

Conditions

  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation

Interventions

DIETARY_SUPPLEMENT

DIM-Avail 100mg

DIM 100 mg\*1 daily for 2 years

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • David Margel, MD, PhD · Rabin Medical Center, Beilinson campus, Petah-Tikva, Israel

  • Rinat Yerushalmi, MD · Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-11
Primary Completion
2018-10-10
Completion
2018-10-10

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02197000 on ClinicalTrials.gov